Search

Your search keyword '"Kozaki, Shunji"' showing total 498 results
Start Over Author "Kozaki, Shunji"
498 results on '"Kozaki, Shunji"'

11. Remarks on Cheon’s Algorithms for Pairing-Related Problems

Author

Kozaki, Shunji, Kutsuma, Taketeru, Matsuo, Kazuto, Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Doug, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Takagi, Tsuyoshi, editor, Okamoto, Tatsuaki, editor, Okamoto, Eiji, editor, and Okamoto, Takeshi, editor

Published
2007
Full Text
View/download PDF

19. Dissecting the L Chains of Clostridial Neurotoxins

Author

Niemann, Heiner, Binz, Thomas, Grebenstein, Oliver, Kurazono, Hisao, Kalkuhl, Arno, Yamasaki, Shinji, Eisel, Ulrich, Pohlner, Johannes, Schneider, Germar, Krivan, Viliam, Kozaki, Shunji, Mochida, Sumiko, Tauc, Ladislav, Poulain, Bernard, and DasGupta, Bibhuti R., editor

Published
1993
Full Text
View/download PDF

32. A1型毒素との比較でボツリヌス神経毒素A2型、新規低分子量神経毒素A2NTXの臨床安全性と忍容性

Author

Takeuchi, Toshiaki, Okuno, Tsuyoshi, Miyashiro, Ai, Kohda, Tomoko, Miyamoto, Ryosuke, Izumi, Yuishin, Kozaki, Shunji, and Kaji, Ryuji

Subjects
safety, subtype A2, botulinum toxin, clinical tolerability, patients
Abstract

All the botulinum type A neurotoxins available for clinical use are of the A1 subtype. We developed a subtype A2 low-molecular-weight (150 kD (kilo Dalton)) neurotoxin (A2NTX) with less spread and faster entry into the motor nerve terminal than A1 in vitro and in vivo. Preliminary clinical studies showed that its efficacy is superior to A1 toxins. We conducted an open study exploring its safety and tolerability profile in comparison with A1LL (LL type A1 toxin, or onabotulinumtoxinA) and a low-molecular-weight (150 kD) A1 neurotoxin (A1NTX). Those who had been using A1LL (n = 90; 50–360 mouse LD50 units) or A1NTX (n = 30; 50–580 units) were switched to A2NTX (n = 120; 25–600 units) from 2010 to 2018 (number of sessions ~27, cumulative doses ~11,640 units per patient). The adverse events for A2NTX included weakness (n = 1, ascribed to alcoholic polyneuropathy), dysphagia (1), local weakness (4), and spread to other muscles (1), whereas those for A1LL or A1NTX comprised weakness (n = 2, A1NTX), dysphagia (8), ptosis (6), local weakness (7), and spread to other muscles (15). After injections, 89 out of 120 patients preferred A2NTX to A1 for the successive sessions. The present study demonstrated that A2NTX had clinical safety up to the dose of 500 units and was well tolerated compared to A1 toxins

Published
2021

42. Genetic analysis of type E botulinum toxin-producing Clostridium butyricum strains

Author

Wang, Xingmin, Maegawa, Tsuneo, Karasawa, Tadahiro, Kozaki, Shunji, Tsukamoto, Kentaro, Gyobu, Yotaku, Yamakawa, Kiyotaka, Oguma, Keiji, Sakaguchi, Yoshihiko, and Nakamura, Shinichi

Subjects
Clostridium -- Research, Biological sciences
Abstract

Clostridium butyricum appears to occur all over the world, according to researchers who analyzed the type E botulinum toxin gene from the bacterium using the random amplified polymorphic DNA (RAPD), pulsed-field gel electrophoresis, and Southern blot hybridization. The bacterial samples came from cases of food-borne botulism in Italy and China, and from soil in China.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results